Jin Chun Paeng
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (34)
Year:
2026
Year:
2026
Year:
2026
Purpose Lymphoscintigraphy is crucial for diagnosis of lymphatic abnormality and sentinel lymph node (SLN) detection in surgery. We investigated the feasibility of [ 99m Tc]Tc-mannosylated human serum albumin (MSA) as a new imaging agent for lymphoscintigraphy. Methods In the first part, three healthy volunteers were enrolled to evaluate the safety and basic efficacy of [ 99m Tc]Tc-MSA, using [ 99m Tc]Tc-phytate as a comparator. In the volunteers, the two radiopharmaceuticals were injected into the interphalangeal web of bilateral feet on different days. Whole-body scans were performed serially until 24 h after the injection. The biodistribution, radiation dosimetry, and safety were evaluated. In the second step, six breast cancer patients planned for operation were enrolled. SLN imaging was performed using [ 99m Tc]Tc-MSA two days before operation, and again on the day of operation using [ 99m Tc]Tc-phytate. The efficacy of SLN detection was evaluated using a visual grade system and compared between the two different radiopharmaceuticals. Results [ 99m Tc]Tc-MSA and [ 99m Tc]Tc-phytate show comparable biodistribution in evaluated organs and inguinal lymph node stations. [ 99m Tc]Tc-MSA showed relatively slower migration speed through lymphatic vessels and clearer visualization of lymphatics than [ 99m Tc]Tc-phytate. No abnormality was observed in safety parameters. In the radiation dosimetry, whole body dose at usual injection dose (74 MBq) was estimated to be 236 µSv. In SLN imaging in breast cancer patients, [ 99m Tc]Tc-MSA showed higher target-to-background ratio than [ 99m Tc]Tc-phytate, with clear visualization of SLN with both imaging agents. Conclusion [ 99m Tc]Tc-MSA is a safe and effective imaging agent for lymphoscintigraphy. Particularly, [ 99m Tc]Tc-MSA can be a more effective radiopharmaceutical for SLN imaging than [ 99m Tc]Tc-phytate.
Year:
2026
Year:
2026
Objectives To evaluate the outcomes of yttrium-90 radioembolization (glass microspheres) in patients with unilobar hepatocellular carcinoma (HCC) and portal vein invasion (PVI) who have preserved liver function. Materials and methods This study included 48 patients with unilobar HCC and PVI, all with Child-Pugh A, treated with radioembolization at a single institution between January 2016 and December 2023. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST) and localized mRECIST. Overall survival (OS) and prognostic factors were evaluated using time-to-event analyses. The mean tumor absorbed dose (TAD) threshold for achieving complete response (CR) by localized mRECIST was determined using receiver operating characteristic analysis, while the threshold associated with significantly longer OS was identified using the minimum p -value approach. Results Objective response rates were 83% (40/48) by mRECIST and 88% (42/48) by localized mRECIST. The median OS was 47.2 months (95% CI, 19.1–52.1 months). The TAD was the only significant predictor of OS ( p = 0.032, hazard ratio = 0.862 per 100 Gy, 95% CI = 0.753–0.988). A mean TAD > 574 Gy provided 50% sensitivity and 86% specificity for predicting CR by localized mRECIST, while a threshold of 586 Gy was proposed to significantly extend OS (median OS, 49.5 months for > 586 Gy and 21.9 months for ≤ 586 Gy; p = 0.021). Conclusion Radioembolization is effective for HCC with localized PVI in patients with preserved liver function, and a mean TAD > 600 Gy is proposed to achieve improved oncologic outcomes. Key Points Question What is the optimal radioembolization approach and its outcome for hepatocellular carcinoma with localized portal vein invasion (Vp1–3) in patients with preserved liver function? Findings A tumor absorbed dose exceeding 600 Gy via a tandem approach achieved complete response rates above 80% and median overall survival longer than 49.5 months. Clinical relevance Ablative radioembolization, delivering a tumor absorbed dose exceeding 600 Gy via a tandem approach, should be considered for hepatocellular carcinoma with localized portal vein tumor thrombosis (Vp1–3) in patients with preserved liver function and no extrahepatic spread. Graphical Abstract
Year:
2026
Year:
2025
Background/Objectives: The neutrophil-to-lymphocyte ratio (NLR), a marker of systemic inflammation, is a known predictor of cardiovascular disease and overall mortality. We examined the relationship between the NLR and the metabolic activity of hematopoietic organs and visceral fat, and their association with the risk of atherosclerotic cardiovascular disease (ASCVD) in an asymptomatic healthy population. Methods: We retrospectively analyzed individuals who underwent F-18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) as part of their health check-ups. Metabolic activity was quantified using standardized uptake values (SUVs) from the lumbar vertebral bone marrow, spleen, visceral, and subcutaneous fat, normalized to target-to-background ratios (TBRs) using the superior vena cava. NLR was calculated from absolute neutrophil and lymphocyte counts. Correlations between NLR, clinical parameters, organ TBRs, and ASCAD risk were analyzed. Results: Among 303 participants from three hospitals, the median NLR was 1.5 (range: 0.5–5.55). NLR showed weak correlation with the TBRs of bone marrow, visceral fat, and subcutaneous fat, as well as high-density lipoprotein cholesterol and body mass index (BMI). In logistic regression analysis adjusted for age and sex, BMI and the TBRs of bone marrow and visceral fat were independent predictors of elevated NLR (≥ 1.5). When integrating these parameters, NLR demonstrated strong predictive performance for identifying a high ASCVD risk (≥20% over 10 years), with an area under the curve of 0.826. Conclusions: In an asymptomatic healthy population, NLR is associated with FDG metabolic parameters of hematopoietic organs and adipose tissue. These combined measures may serve as valuable marker for identifying individuals at elevated ASCVD risk.
Year:
2025
Autism spectrum disorder (ASD) is a heterogeneous group of neurodevelopmental disorders characterized by social communication deficits and repetitive behaviors. Although our current understanding the mechanisms underlying ASD is growing, effective treatment options are still underdevelopment. Extracellular vesicles derived from the probiotic Lactobacillus paracasei (LpEV) have shown neuroprotective effects in both in vitro and in vivo models. Here we investigate whether LpEV can alleviate core symptoms in genetic ASD models that exhibit accumulated developmental deficits. Dopamine receptor D2 (Drd2)-knockout (KO) mice exhibit social behavior deficits and excessive grooming, core symptoms of ASD. LpEV treatment significantly improves these autistic-like behaviors in Drd2-KO mice, suggesting that LpEVs can mitigate the persistent dysregulation of signaling pathways in these mice. RNA sequencing followed by Gene Ontology enrichment analysis of LpEV-treated Drd2-KO mice identifies distinct groups of genes altered in the brain of Drd2-KO mice, which were reversed by LpEV treatment. Notably, a high proportion of these genes overlap significantly with known ASD genes in the SFARI database, strengthening the potential of LpEV to target relevant pathways in ASD. Further investigation identifies oxytocin and oxytocin receptor (Oxtr) as potential therapeutic targets. LpEV treatment significantly improves autistic-like behaviors in Oxtr-KO heterozygous mice, adenylyl cyclase-5 KO mice and Shank3-KO mice, suggesting its therapeutic potential to target ASD through broader mechanisms beyond a single gene pathway. These results highlight the therapeutic potential of LpEV in reversing the accumulated dysregulated signaling pathways leading to ASD symptoms and improving autistic-like behaviors.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (16)
Jaeryuk Kim
Clinical Associate Professor
Samsung Medical Center
Tae-Kyung Kim
Korea National Sport University
Yun Young Choi
Hanyang University Guri Hospital
Eun Ju Cho
Seoul National University
Hyo-Cheol Kim
Clinical Professor
Seoul National University Hospital
Yoon Jun Kim
Professor
Seoul National University College of Medicine
So-Ryoung Lee
Seoul National University Hospital
Jung‐Hwan Yoon
Professor
Seoul National University Hospital
Soo Jin Lee
Hanyang University Guri Hospital
Jeong-Hoon Lee
Professor
Seoul National University Hospital
Yun Bin Lee
Associate Professor
Seoul National University Hospital
Jahae Kim
Chonnam National University Medical School
Jin Woo Choi
Assistant Professor
Seoul National University Hospital
Seil Oh
Seoul National University College of Medicine
DO HOON KIM
Seoul National University Hospital
Jin Wook Chung
Professor
Seoul National University College of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.